CYBN
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Cybin announces $175 million registered direct offeringOct 28, 2025
- Cybin completes enrollment in Phase 2 study evaluating CYB004 for treatment of generalized anxiety disorderSep 8, 2025
- Cybin receives Australian approval for EMBRACE, a multinational pivotal study evaluating CYB003 for adjunctive treatment of major depressive disorderAug 26, 2025
- Cybin receives European approval for EMBRACE, a multinational Phase 3 study evaluating CYB003 for adjunctive treatment of major depressive disorderAug 7, 2025
- Cybin receives UK MHRA approval to begin EMBRACE, a multinational pivotal study of CYB003 for adjunctive treatment of major depressive disorderJul 17, 2025